Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
T helper 17 (Th17) cell activation refers to the process by which naive CD4+ T cells differentiate into Th17 cells and become functionally active. Th17 cells are a distinct subset of pro-inflammatory T helper lymphocytes, primarily defined by their production of interleukin-17A (IL-17A), but also IL-17F, IL-21, and IL-22. These cells play crucial roles in host defense against extracellular pathogens at mucosal and epithelial barriers, as well as in the pathogenesis of various autoimmune and inflammatory diseases. The differentiation from naive CD4+ T cell to activated Th17 cell involves antigen presentation, and the presence of specific cytokines determines lineage commitment, notably TGFβ combined with IL‑6 or IL‑21, and later IL-23 for maintenance.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on T helper 17 cell activation (None).